HTG Molecular Diagnostics (HTGM) Short Interest Ratio & Short Volume

Short interest is the volume of HTG Molecular Diagnostics shares that have been sold short but have not yet been covered or closed out. As of May 31st, investors have sold 2,700 shares of HTGM short. 0.13% of HTG Molecular Diagnostics' shares are currently sold short. Learn More on HTG Molecular Diagnostics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.13% of HTG Molecular Diagnostics' floating shares are currently sold short.

HTG Molecular Diagnostics saw a drop in short interest in May. As of May 31st, there was short interest totaling 2,700 shares, a drop of 95.4% from the previous total of 58,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

HTG Molecular Diagnostics currently has issued a total of 2,210,000 shares. Some of HTG Molecular Diagnostics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. HTG Molecular Diagnostics currently has a public float of 2,120,000 shares.

0.13% of HTG Molecular Diagnostics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to HTG Molecular Diagnostics: HTG Molecular Diagnostics, Inc. (0.07%), Singular Genomics Systems, Inc. (2.91%), Talis Biomedical Co. (0.55%), Accelerate Diagnostics, Inc. (1.94%), Telesis Bio, Inc. (0.02%), Calithera Biosciences, Inc. (0.43%), Clever Leaves Holdings Inc. (0.52%), Cocrystal Pharma, Inc. (0.06%), CytoMed Therapeutics Limited (1.42%).

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.00 billion), Suncor Energy Inc. ($2.98 billion), Charter Communications, Inc. ($2.88 billion), Occidental Petroleum Corporation ($2.79 billion), Moderna, Inc. ($2.39 billion), Snowflake Inc. ($2.38 billion), Coinbase Global, Inc. ($2.22 billion), Palantir Technologies Inc. ($2.18 billion), T. Rowe Price Group, Inc. ($2.03 billion), and Verisk Analytics, Inc. ($2.02 billion). View all of the most shorted stocks.

Short selling HTGM is an investing strategy that aims to generate trading profit from HTG Molecular Diagnostics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for HTG Molecular Diagnostics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of HTGM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HTGM, twice per month. The most recent reporting period available is May, 31 2023.